インターフェロン-ガンマエンドタイプによる敗血症において期待される臨床効果をもたらすエマパルマブ治療(EMBRACE試験) (EMBRACE)
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
調査の概要
詳細な説明
The EMBRACE trial aims to generate proof-of-concept if treatment with emapalumab, a monoclonal antibody which blocks IFNγ signaling, may improve the outcome of patients with sepsis driven by the IDS endotype. In EMBRACE, two different dose regimens of emapalumab are administered in order to: a) investigate which dose regimen may provide most of efficacy in the decrease of SOFA score, a new endpoint for sepsis suggested already by others; b) investigate which dose regimen better attains the pharmacodynamic goal of emapalumab defined as the decrease of blood CXCL9; and c) compare the efficacy of the two dose regimens with placebo treated patients.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Alexandroupoli、ギリシャ
- Intensive Care Unit, Alexandroupolis University General Hospital
-
Athens、ギリシャ
- 4th Department of Internal Medicine, ATTIKON University General Hospital
-
Athens、ギリシャ
- Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
-
Athens、ギリシャ
- 3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens、ギリシャ
- Intensive Care Unit I, KAT Attica General Hospital
-
Athens、ギリシャ
- Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
-
Athens、ギリシャ
- Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
-
Athens、ギリシャ
- Intensive Care Unit, Asklipieio Voulas General Hospital
-
Athens、ギリシャ
- Intensive Care Unit, Ippokrateio Athens General Hospital
-
Athens、ギリシャ
- Intensive Care Unit, Laiko Athens General Hospital
-
Athens、ギリシャ
- New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
-
Athens、ギリシャ
- Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
-
Pátrai、ギリシャ
- Intensive Care Unit, Patras University General Hospital
-
Thessaloniki、ギリシャ
- 1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
-
Thessaloniki、ギリシャ
- Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
-
Thessaloniki、ギリシャ
- Intensive Care Unit, 424 General Military Training Hospital
-
Thessaloniki、ギリシャ
- Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
-
Thessaloniki、ギリシャ
- Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
-
Thessaloniki、ギリシャ
- Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
-
Thessaloniki、ギリシャ
- Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
-
Thessaloniki、ギリシャ
- Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
-
-
Attica
-
Elefsina、Attica、ギリシャ
- 1st Department of Internal Medicine, Thriasio Elefsis General Hospital
-
Kifissia、Attica、ギリシャ
- Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
-
-
Crete
-
Heraklion、Crete、ギリシャ
- Intensive Care Unit, University General Hospital of Heraklion
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Provide written informed consent
- Adults (≥18 years) of male or female sex
- Diagnosis of community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), intrabdominal infection (IAI), acute pyelonephritis (AP), primary bloodstream infection (BSI) and viral respiratory infections.
- Sepsis defined by the Sepsis-3 definitions. This is defined as any new infection which is accompanied by an increase of the total baseline SOFA score by at least 2 points. The total baseline SOFA score is calculated by the medical comorbidities and by the evaluation of clinical variables before the sepsis episode in the case of hospital-acquired sepsis. In the case of patients with unknown baseline SOFA score, sepsis is defined as any new infection accompanied by total SOFA score 2 or more.
- Willingness to use effective contraceptive methods during the period from the start of the study drug to 6 months after the administration of the last dose of the study drug, in patients of reproductive age.
- Serological documentation of IDS defined as detectable blood IFNγ and CXCL9 more than 2,200 pg/ml. IFNγ and CXCL9 are measured in the central study lab by an enzyme immunosorbent assay.
- Absence of sepsis-induced immunoparalysis (SII). This is defined as ≥8000 of HLA-DR receptors on CD45/CD14-monocytes measured by flow-cytometry in the central lab using the BD™ fluorescence assay9.
Exclusion Criteria:
- Body weight more than 104 kg
- Intake of any other biological during the last 30 days prior screening except for the intake of anakinra or tocilizumab for patients with active infection by SARS-CoV-2
- Intake of any Janus kinase inhibitors during the last 30 days prior screening except for the intake of baricitinib for patients with active infection by SARS-CoV-2
- Known active infection by Mycobacterium tuberculosis or other mycobacteria. These patients may be enrolled in the trial if treatment against infection by Mycobacterium tuberculosis or other mycobacteria has been initiated
- Known active infection by VZV (varicella zoster virus) or by Histoplasma capsulatum or by Leishmania spp. These patients may be enrolled in the trial if treatment against infection by VZV or Histoplasma capsulatum has been initiated
- Known active infection by the hepatitis B virus, by the hepatitis C virus and by cytomegalovirus
- Vaccination the last 12 weeks before screening with BCG vaccine
- Vaccination with any live or attenuated live vaccine (other than BCG) the last 12 weeks before screening
- Known allergy or hypersensitivity reactions to emapalumab
- Patients living with the human immunodeficiency virus (HIV)
- Patients with stage IV solid or hematologic malignancy
- Patients with neutropenia (less than 1,000 neutrophils/mm3)
- Patients transplanted for solid organ or stem cells
- Pregnancy or lactation
- Participation in any other interventional trial the last 28 days prior to day 1
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Standard-of-care (SoC) treatment and placebo drug. |
250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply |
|
アクティブコンパレータ:Emapalumab Group 1
SoC treatment and a low dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
他の名前:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
他の名前:
|
|
アクティブコンパレータ:Emapalumab Group 2
SoC treatment and a high dose of emapalumab. |
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
他の名前:
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Decrease of SOFA score by the end-of-treatment
時間枠:From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
The study primary endpoint is the decrease of SOFA score by the end-of-treatment (EOT). This is defined as either a) at least 1.4 points decrease of mean SOFA score calculated between days 1 and EOT from SOFA score of day 0; OR b) at least 2 points decrease of SOFA at EOT from day 0. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
EOT による SOFA スコア反応を達成するために各グループで必要な用量の数。
時間枠:各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
|
|
28日以内の死亡率
時間枠:入会から入会後28日まで。
|
入会から入会後28日まで。
|
|
|
The rate of serious TEAEs and non-serious TEAEs
時間枠:From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
Comparison of the rate of serious TEAEs and non-serious TEAEs between the three groups of treatment. |
From enrollment to the end of observation of each of the study participants, which is 120 days plus or minus 3 days, after each participant's enrollment.
|
|
The change of the SOFA score from day 0 until day 7
時間枠:From enrollment (day 0) to 8 days after enrollment (day 7).
|
Comparison of the change of the SOFA score from day 0 until day 7 |
From enrollment (day 0) to 8 days after enrollment (day 7).
|
|
The change of the SOFA score from 0 until day 28
時間枠:From enrollment to 28 days after enrollment.
|
Comparison of the change of the SOFA score from 0 until day 28 |
From enrollment to 28 days after enrollment.
|
|
The change of the SOFA score from 0 until EOT
時間枠:From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the change of the SOFA score from 0 until EOT |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The pharmacokinetics of emapalumab
時間枠:From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the pharmacokinetics of emapalumab |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes.
時間枠:From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the need to stop the study drug due to drop of the number of HLA-DR receptors on CD14-monocytes. |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
|
The circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment
時間枠:From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
Comparison of the circulating concentrations of IL-6, ferritin, IFNγ and CXCL9 over the days of treatment |
From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
|
その他の成果指標
結果測定 |
時間枠 |
|---|---|
|
治療に対するプロテオミクスプロファイルに関する 3 つの治療グループ間の比較
時間枠:各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
|
治療中のトランスクリプトームプロファイルの変化についての 3 つの治療グループ間の比較
時間枠:各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
|
CD45/CD14 単球上の HLA-DR 受容体の絶対数と比較した、SII 用ポイントオブケア SepsisLoop の診断性能。
時間枠:各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
|
研究対象集団をIDSに分類する診断ツールの開発の可能性に関するスクリーニング時の臨床データとベッドサイドバイオマーカーレベル
時間枠:各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
|
敗血症集団をさまざまなサブグループに分類するスクリーニング時の予後バイオマーカー レベル
時間枠:各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
各研究参加者の登録から治験薬の治療終了まで、2日から29日の範囲です。
|
協力者と研究者
捜査官
- スタディチェア:Evangelos Giamarellos-Bourboulis、Hellenic Institute for the Studies of Sepsis
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- EMBRACE
- 2024-515255-38-00 (Ctis)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。